{"id":76125,"date":"2026-04-23T18:08:18","date_gmt":"2026-04-23T12:38:18","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=76125"},"modified":"2026-04-23T18:08:19","modified_gmt":"2026-04-23T12:38:19","slug":"kopran-q4-results-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/","title":{"rendered":"Kopran Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook"},"content":{"rendered":"<p>Kopran (KOPRAN) is set to announce its Q4 FY26 results in May 2026. Investors and market participants are keenly watching the upcoming quarterly numbers for one of India&#8217;s well-known Pharmaceuticals and Biotech companies. The Q4 FY26 earnings season is a critical period for equity markets as full-year financial performance comes into sharper focus.<\/p>\n<p>Analyst consensus estimates project Kopran Q4 FY26 revenue at Rs 162 Cr, representing a year-on-year growth of approximately 7%, while PAT is estimated at Rs 16 Cr, a growth of approximately 14% compared to the same quarter in FY25. These estimates reflect the sector outlook and company-specific operational momentum observed over the preceding quarters.<\/p>\n<p>In this article, we provide a detailed preview of Kopran Q4 results 2026, including the expected date, key financial estimates, five growth factors, five risks and the latest analyst ratings. Get free investment insights on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a> to stay ahead of earnings season.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#Kopran_Q4_Results_2026_Date\" title=\"Kopran Q4 Results 2026 Date\">Kopran Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#Why_This_Quarter_Matters_for_Kopran\" title=\"Why This Quarter Matters for Kopran\">Why This Quarter Matters for Kopran<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#Kopran_Q4_FY26_Earnings_Estimates\" title=\"Kopran Q4 FY26 Earnings Estimates\">Kopran Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#5_Key_Factors_That_Will_Drive_Kopran_Q4_FY26_Performance\" title=\"5 Key Factors That Will Drive Kopran Q4 FY26 Performance\">5 Key Factors That Will Drive Kopran Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#1_US_Generics_Business_Recovery\" title=\"1. US Generics Business Recovery\">1. US Generics Business Recovery<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#2_Domestic_Formulations_Growth\" title=\"2. Domestic Formulations Growth\">2. Domestic Formulations Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#3_API_Segment_Expansion_via_China_Plus_One\" title=\"3. API Segment Expansion via China Plus One\">3. API Segment Expansion via China Plus One<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#4_Complex_Generics_and_Biosimilars_Pipeline\" title=\"4. Complex Generics and Biosimilars Pipeline\">4. Complex Generics and Biosimilars Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#5_Emerging_Market_Revenue_Diversification\" title=\"5. Emerging Market Revenue Diversification\">5. Emerging Market Revenue Diversification<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#5_Risks_to_Watch_in_Kopran_Q4_FY26\" title=\"5 Risks to Watch in Kopran Q4 FY26\">5 Risks to Watch in Kopran Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#1_USFDA_Inspection_and_Import_Alert_Risk\" title=\"1. USFDA Inspection and Import Alert Risk\">1. USFDA Inspection and Import Alert Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#2_US_Generics_Price_Erosion\" title=\"2. US Generics Price Erosion\">2. US Generics Price Erosion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#3_Raw_Material_Cost_Pressure\" title=\"3. Raw Material Cost Pressure\">3. Raw Material Cost Pressure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#4_DPCO_Price_Control_Impact\" title=\"4. DPCO Price Control Impact\">4. DPCO Price Control Impact<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#5_Currency_Risk_on_Export_Revenues\" title=\"5. Currency Risk on Export Revenues\">5. Currency Risk on Export Revenues<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#Kopran_Share_Price_and_Analyst_Ratings\" title=\"Kopran Share Price and Analyst Ratings\">Kopran Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#What_is_the_Kopran_Q4_results_2026_date\" title=\"What is the Kopran Q4 results 2026 date?\">What is the Kopran Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#What_is_the_Kopran_Q4_FY26_PAT_estimate\" title=\"What is the Kopran Q4 FY26 PAT estimate?\">What is the Kopran Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#What_is_Kopran_share_price_ahead_of_Q4_results\" title=\"What is Kopran share price ahead of Q4 results?\">What is Kopran share price ahead of Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#Will_Kopran_declare_a_dividend_in_Q4_2026\" title=\"Will Kopran declare a dividend in Q4 2026?\">Will Kopran declare a dividend in Q4 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#Which_analysts_have_a_Buy_rating_on_Kopran\" title=\"Which analysts have a Buy rating on Kopran?\">Which analysts have a Buy rating on Kopran?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#What_were_Kopran_Q3_FY26_results\" title=\"What were Kopran Q3 FY26 results?\">What were Kopran Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#When_do_Infosys_and_TCS_announce_Q4_results_2026\" title=\"When do Infosys and TCS announce Q4 results 2026?\">When do Infosys and TCS announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#Is_Kopran_a_good_investment_ahead_of_Q4_results\" title=\"Is Kopran a good investment ahead of Q4 results?\">Is Kopran a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/kopran-q4-results-2026\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Kopran_Q4_Results_2026_Date\"><\/span><strong>Kopran Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Access premium research and earnings previews on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a> before every major result announcement.<\/p>\n<p>The Kopran Q4 FY26 results are expected to be declared in May 2026. The board of directors will convene a meeting to approve the audited financial results for the quarter and full year ended March 31, 2026. The exact date will be intimated through BSE and NSE filings. Investors should monitor exchange announcements for the confirmed date.<\/p>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<td><strong>Company<\/strong><\/td>\n<td><strong>Q4 Results Date<\/strong><\/td>\n<td><strong>Key Watch<\/strong><\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">TCS<\/a><\/td>\n<td>April 9, 2026<\/td>\n<td>Revenue growth and deal wins<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Infosys<\/a><\/td>\n<td>April 23, 2026<\/td>\n<td>FY27 guidance and margin outlook<\/td>\n<\/tr>\n<tr>\n<td>Kopran<\/td>\n<td>May 2026 (Expected)<\/td>\n<td>Revenue, PAT and dividend announcement<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_This_Quarter_Matters_for_Kopran\"><\/span><strong>Why This Quarter Matters for Kopran<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The pharma sector is expected to deliver solid Q4 FY26 performance with stabilising US generic pricing, robust domestic formulation growth and a deepening complex generics pipeline supporting both revenue and margin expansion.<\/p>\n<p>For Kopran specifically, Q4 FY26 is a critical quarter as it determines the full-year FY26 performance trajectory. The management&#8217;s commentary on FY27 outlook, any guidance revision and dividend announcement will be equally important for investor sentiment as the headline revenue and PAT numbers.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Kopran_Q4_FY26_Earnings_Estimates\"><\/span><strong>Kopran Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Screen Kopran fundamentals, historical financials and technical indicators on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p>\n<p>Based on analyst consensus and sector-level research, Kopran is expected to report Q4 FY26 revenue of Rs 162 Cr, up 7% year-on-year. PAT is estimated at Rs 16 Cr, reflecting 14% growth. EBITDA margin is expected to come in at approximately 9.9%, showing improvement compared to the year-ago quarter driven by operating leverage and cost efficiencies.<\/p>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<td><strong>Metric<\/strong><\/td>\n<td><strong>Q3 FY26 (Actual)<\/strong><\/td>\n<td><strong>Q4 FY26 (Estimate)<\/strong><\/td>\n<td><strong>YoY Change<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Revenue (Rs Cr)<\/td>\n<td>152<\/td>\n<td>162<\/td>\n<td>+7% (Est)<\/td>\n<\/tr>\n<tr>\n<td>PAT (Rs Cr)<\/td>\n<td>14<\/td>\n<td>16<\/td>\n<td>+14% (Est)<\/td>\n<\/tr>\n<tr>\n<td>PAT Margin (%)<\/td>\n<td>9.2%<\/td>\n<td>9.9%<\/td>\n<td>Expanding<\/td>\n<\/tr>\n<tr>\n<td>Dividend History<\/td>\n<td colspan=\"2\">Rs 1.00 per share<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<tr>\n<td>Dividend Expectation<\/td>\n<td colspan=\"2\">Rs 1.50 final dividend expected<\/td>\n<td>&#8211;<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Beyond the headline numbers, key metrics to watch include EBITDA margin trajectory, working capital management, order book or pipeline commentary and management guidance for FY27. These forward-looking indicators often have a larger impact on stock price reaction than the reported PAT figure alone.<\/p>\n<p>Track Kopran fundamentals and compare it with sector peers on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a> for in-depth financial analysis.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"5_Key_Factors_That_Will_Drive_Kopran_Q4_FY26_Performance\"><\/span><strong>5 Key Factors That Will Drive Kopran Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_US_Generics_Business_Recovery\"><\/span><strong>1. US Generics Business Recovery<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Pricing erosion in US generics has moderated significantly. New ANDA approvals and first-to-file opportunities in high-value molecules are providing meaningful revenue upside for companies with deep US pipelines.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Domestic_Formulations_Growth\"><\/span><strong>2. Domestic Formulations Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s domestic pharma market continues growing at 9 to 11 percent, driven by chronic therapy categories including cardiovascular, diabetes and respiratory, and expanding healthcare access in semi-urban India.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_API_Segment_Expansion_via_China_Plus_One\"><\/span><strong>3. API Segment Expansion via China Plus One<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>China Plus One sourcing diversification by global pharma companies is creating strong and durable demand for Indian API manufacturers with robust quality regulatory track records.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_Complex_Generics_and_Biosimilars_Pipeline\"><\/span><strong>4. Complex Generics and Biosimilars Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Companies investing in complex injectables, biosimilars and specialty drugs are building differentiated pipelines that command significantly higher pricing and margins than standard generics.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_Emerging_Market_Revenue_Diversification\"><\/span><strong>5. Emerging Market Revenue Diversification<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Africa, Latin America and Southeast Asia revenues are growing robustly, providing geographical diversification beyond the US and India and reducing single-market concentration risk.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Kopran_Q4_FY26\"><\/span><strong>5 Risks to Watch in Kopran Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_USFDA_Inspection_and_Import_Alert_Risk\"><\/span><strong>1. USFDA Inspection and Import Alert Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>USFDA facility inspections and import alerts remain a persistent overhang; any adverse observation or warning letter can materially disrupt US revenues for multiple quarters.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_US_Generics_Price_Erosion\"><\/span><strong>2. US Generics Price Erosion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Competition from Chinese and domestic US manufacturers can re-intensify pricing pressure in base generics molecules, eroding volumes and realisations unexpectedly.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Raw_Material_Cost_Pressure\"><\/span><strong>3. Raw Material Cost Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>API and solvent prices, particularly China-sourced intermediates, can spike and compress gross margins sharply if supply disruptions occur.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_DPCO_Price_Control_Impact\"><\/span><strong>4. DPCO Price Control Impact<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Inclusion of additional drugs in the National List of Essential Medicines limits domestic pricing flexibility and can restrict revenue growth for affected portfolios.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_Currency_Risk_on_Export_Revenues\"><\/span><strong>5. Currency Risk on Export Revenues<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Weakness in export destination currencies against INR reduces international revenue realisation and compresses overseas profitability.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Kopran_Share_Price_and_Analyst_Ratings\"><\/span><strong>Kopran Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Kopran (KOPRAN) is currently trading at Rs 182 with a market capitalisation of approximately Rs 565 Cr. The stock has been under investor scrutiny ahead of Q4 results, with analysts closely monitoring sector trends and company-specific developments that could influence the quarterly outcome.<\/p>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<td><strong>Brokerage<\/strong><\/td>\n<td><strong>Rating<\/strong><\/td>\n<td><strong>Target Price<\/strong><\/td>\n<td><strong>Thesis<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Bernstein<\/td>\n<td><strong>Outperform<\/strong><\/td>\n<td>Rs 214<\/td>\n<td>US generics recovery and complex pipeline launches<\/td>\n<\/tr>\n<tr>\n<td>CLSA<\/td>\n<td><strong>Buy<\/strong><\/td>\n<td>Rs 214<\/td>\n<td>Domestic growth and API China Plus One opportunity<\/td>\n<\/tr>\n<tr>\n<td>JM Financial<\/td>\n<td><strong>Buy<\/strong><\/td>\n<td>Rs 214<\/td>\n<td>Margin expansion and emerging market revenue growth<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Kopran share price, analyst ratings and earnings updates in real time.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Kopran heads into Q4 FY26 with reasonable earnings visibility, supported by sector tailwinds and company-specific operational improvements. The Q4 numbers will be an important validation of the full-year FY26 investment thesis. Investors should track the results date, dividend announcement and management commentary on FY27 guidance closely. For ongoing research and stock insights, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p>\n<p>This article is for informational and educational purposes only and does not constitute investment advice. All estimates are based on publicly available analyst research and are subject to change. Consult a SEBI-registered advisor before making investment decisions.<\/p>\n<p>For more Q4 FY26 results previews, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Kopran_Q4_results_2026_date\"><\/span><strong>What is the Kopran Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Kopran Q4 FY26 results are expected to be announced in May 2026. The exact date will be confirmed by the company&#8217;s board through a BSE and NSE filing. Check <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a> for real-time updates.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Kopran_Q4_FY26_PAT_estimate\"><\/span><strong>What is the Kopran Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Analyst consensus estimates put Kopran Q4 FY26 PAT at approximately Rs 16 Cr, representing a year-on-year growth of approximately 14% compared to the same quarter in FY25. These are estimates and actual results may vary.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Kopran_share_price_ahead_of_Q4_results\"><\/span><strong>What is Kopran share price ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Kopran share price (ticker: KOPRAN) is trading near Rs 182 with a market capitalisation of approximately Rs 565 Cr. Investors should track the stock on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a> for live price and fundamental data.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Will_Kopran_declare_a_dividend_in_Q4_2026\"><\/span><strong>Will Kopran declare a dividend in Q4 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Based on available analyst estimates and historical dividend patterns, Rs 1.50 final dividend expected. Kopran&#8217;s historical dividend record shows Rs 1.00 per share. A final dividend announcement is typically made at the board meeting where Q4 results are declared.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_analysts_have_a_Buy_rating_on_Kopran\"><\/span><strong>Which analysts have a Buy rating on Kopran?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Based on publicly available brokerage research, Bernstein has a Outperform rating on Kopran with the thesis: US generics recovery and complex pipeline launches. Ratings are subject to change; always consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Kopran_Q3_FY26_results\"><\/span><strong>What were Kopran Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Kopran reported Q3 FY26 revenue of Rs 152 Cr and PAT of Rs 14 Cr. The management commentary highlighted key operational metrics and sector-specific guidance that set the expectations benchmark for Q4 FY26 performance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_do_Infosys_and_TCS_announce_Q4_results_2026\"><\/span><strong>When do Infosys and TCS announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">TCS announced its Q4 FY26 results on April 9, 2026<\/a>, while <a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Infosys announced on April 23, 2026<\/a>. These results set the broader IT sector tone and benchmark for Q4 earnings season.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Kopran_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Is Kopran a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Kopran operates in the Pharmaceuticals and Biotech sector and its Q4 FY26 performance will be determined by the factors outlined above. Any investment decision should be based on your personal financial goals, risk tolerance and a consultation with a SEBI-registered investment advisor. Access research on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p>\n<p><strong>Disclaimer:<\/strong> Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE and BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/indraprastha-medical-corporation-q4-results-2026\">Indraprastha Medical Corporation Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/indogulf-cropsciences-q4-results-2026\">Indogulf Cropsciences Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/jayant-agro-organics-q4-results-2026\">Jayant Agro Organics Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/jamna-auto-industries-q4-results-2026-2\">Jamna Auto Industries Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/iris-clothings-q4-results-2026\">Iris Clothings Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Get the complete Kopran Q4 Results 2026 preview including expected date, revenue estimate of Rs 162 Cr, PAT estimate of Rs 16 Cr and latest analyst ratings. Updated on Univest.<\/p>\n","protected":false},"author":28,"featured_media":76460,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858],"class_list":["post-76125","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1776947905:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["74"],"rank_math_title":["Kopran Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook"],"rank_math_description":["Kopran Q4 Results 2026 preview including expected date, revenue estimate of Rs 162 Cr, PAT estimate of Rs 16 Cr and latest analyst ratings. Updated on Univest."],"rank_math_focus_keyword":["Kopran Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_wp_old_slug":["blogs-kopran-q4-results-2026-preview"],"_thumbnail_id":["76460"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["9012"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/23180800\/Kopran-Q4-Results-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/76125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=76125"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/76125\/revisions"}],"predecessor-version":[{"id":76461,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/76125\/revisions\/76461"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/76460"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=76125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=76125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=76125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}